This Q&A blog discusses how the biopharma partnering industry will change over the next 5 years and what the most important factors in successful dealmaking are.
Dr. Jeff Bockman, Vice President of Defined Health
Jeff, a panelist in our webinar "What's the role of Non-IO in an IO world," discusses what's hot in the immuno-therapy landscape, partnering immuno-therapy with non-immuno therapy, and how soon a cure could be in place with these new combination therapies.
Gautam Aggarwal, Partner, Triangle Insights Group, LLC
Given the rapid pace of innovation in today’s Life Sciences industry, it has become more important than ever for biotech companies to align themselves with strategic partners in order to advance drug candidates. Guatam discusses how to optimize the commercialization of biopharma assets.
Jim McCarthy is CEO of CorpDevVentures
We sat with Jim McCarthy, who has over 25 years in business development, to talk about tips on when to share documents during due diligence. Jim disucsses how to structure a deal during due diligence, what to look for when selecting a secure document sharing tool and more.
Linda Pullan, PhD, Pullan Consulting
We sat down with partnership expert Linda Pullan, who has been consulting biotechs for the past decade to get her insights on dealmaking. She discusses what the most common mistakes are and what leaders can do to ensure a successful deal.
Sarah Arth, Vice President of Education at the Biotechnology Innovation Organization
The BIO International Convention is the largest and most influencial global event for the biotechnology industry. To learn more about why 15,000 biotech professionals from more than 70 countries attend, we sat down with Sarah.
Ravi Kiron, Managing Partner at Biopharm Strategy Advisors
We sat down with Dr. Ravi Kiron, moderator of the same titled webinar, to find out whether the microbiome therapeutic area can revolutionize the healthcare industry of the future or whether we are treading on dangerous ground that we know little about.